Source comparison
Melanotan II: Full Comparison
The table below contrasts Melanotan II with its close analog Melanotan I (afamelanotide), UV-induced tanning, and topical dihydroxyacetone (DHA) self-tanners across mechanism, receptor selectivity, photoprotection, and regulatory status. Melanotan II (MT2) Syn
This comparison does not assign a generated winner or score.
- The table below contrasts Melanotan II with its close analog Melanotan I (afamelanotide), UV-induced tanning, and topical dihydroxyacetone (DHA) self-tanners across mechanism, receptor selectivity, photoprotection, and regulatory status.
- Melanotan II (MT2)
- Synthetic α-MSH analog; MC1R/MC3R/MC4R/MC5R agonist
- Non-selective; binds MC1R (pigmentation), MC4R (appetite, libido)
- Theoretical SPF 2–3 via eumelanin; no p53 checkpoint activation
- Not FDA-approved; available via research peptide suppliers
- Effective melanogenesis but systemic off-target effects limit safety profile
- Melanotan I (Afamelanotide)
- Linear α-MSH analog; MC1R-selective agonist
- High MC1R selectivity; minimal MC3R/MC4R binding
- SPF 2–3 demonstrated in clinical trials; FDA-approved for erythropoietic protoporphyria
- FDA-approved (Scenesse) for EPP; prescription implant only
- MC1R-selective design eliminates most non-pigmentation effects; clinical-grade option
- UV-Induced Tanning
- p53-mediated α-MSH secretion post-DNA damage
- Endogenous MC1R activation; includes p53 checkpoint and repair pathways
- SPF 2–4 via eumelanin + thickened stratum corneum + repair enzyme upregulation
- No regulation (natural process)
- Full photoprotective response but requires DNA damage as initiating signal
- DHA Self-Tanners
- Non-enzymatic Maillard reaction; stains stratum corneum proteins
- No receptor binding; purely cosmetic surface reaction
- Zero photoprotection; pigment is keratin-bound, not melanin
- FDA-approved as cosmetic; GRAS status for external use
- Cosmetic only; no melanin synthesis, no UV protection
- Melanotan I (afamelanotide) represents the clinically validated approach to pharmacological tanning—MC1R selectivity eliminates appetite suppression, nausea, and cardiovascular effects while retaining full melanogenic activity. The trade-off is access: afamelanotide is available only as a prescription subcutaneous implant (Scenesse) for patients with erythropoietic protoporphyria, a rare photosensitivity disorder. Melanotan II remains unregulated and is purchased through research peptide suppliers like Real Peptides, where Melanotan 2 MT2 10mg is synthesized to research-grade purity standards with third-party verification.